Musiikkitalo, Helsinki, 7 October 2019

Smart Health for European wellbeing

At the heart of Smart Health is delivering the right treatment to the right patient at the right time, that is faster, better and more personalized healthcare. But what are the prerequisites for Smart Health, and the benefits to the patients, the European healthcare systems and the societies?

Smart Health is not here yet. A functioning, collaborative Smart Health ecosystem could create not only more health but also more economic wellbeing for our continent.

Smart Health for Europe offers health system decision makers a platform to explore the future health ecosystems.

The event is over - thank you to everyone who attended!

Watch the recorded presentations

Topics: Shaping the future

The topics of the event are related to shaping the future of healthcare:

Smart Health community – welcome!

Smart Health stakeholders are warmly welcome to join the event and network with fellow scientists, healthcare leaders and decision makers, members of the Finnish and the European parliaments, biobanks and national centers of excellence, civil servants, MedTech, HealthTech and pharmaceuticals industry, and European and local innovators and investors.

Why Helsinki?

Current development in healthcare builds on technology and data, but these are not enough to reach Smart Health goals. Finland showcases a pioneering combination:

The Finnish EU Presidency 2019 is the time to start creation of a Smart Health roadmap. During the coming years, Europe has the potential to move towards a world leading position in digital healthcare and precision medicine driven healthcare and health systems.

Program


9.00-9.05
Welcome
His Excellency Heinrich Maurer, Ambassador of Switzerland, Mr. Antti Viitanen, Managing Director of Novartis Finland Oy
9.05-9.20
Opening words
Ms. Krista Kiuru, Minister of Family Affairs and Social Services

EU presidencies drive Smart Health forward


9.20-10.20
Smart Health initiative – Finland's role and potential benefits?
Dr. Leena Sarvaranta, Vice President and Head of EU Affairs, VTT
Smart Health – a German view
Ms. Lisa Witte-Stremmel, German Ministry of Health, Division of New Technologies and Data Use

Smart use of data


10.20-11.00
GDPR to boost European research and innovation
Mr. Knut Mager, Novartis Head Global Data Privacy and the Chairman of the Data Protection working group of European Federation of Pharmaceutical Industries and Associations (EFPIA) until June 2019
Secondary use of health data - Findata, the new one-stop-shop
Johanna Seppänen, Director of Social and Health Data Permit Authority
11.00-11.30
Break – music by the Pad Boys
11.30-12.15
Government of Finland accelerating precision medicine – role of the new national centers
Ms. Tuula Helander, Senior Specialist at Ministry of Social Affairs and Health Secretary General, Finnish Cancer Institute
Value based healthcare for better patient outcome
Professor Hartwig Huland, Martini-Klinik Prostate Cancer Center in the University Clinic Hamburg-Eppendorf, Germany

My data, my rights, my health


12.15-12:30
Human-driven and fair data economy – from vision to practice
Ms. Jaana Sinipuro, Project Director (IHAN), Sitra
12.30-13:15
Panel discussion
How do I benefit from my own health data
Ms. Silja Lindqvist, Chair of the Finnish Ichthyosis Association
Learnings from the banking sector
Mr. Petri Nikkilä, EVP Chief Commercial and Digital Officer, Nordea
Ethics in the use of health data
Professor Mika Scheinin, University of Turku
13.15-14.00
Lunch

Smart ecosystems creating Smart Health


14.00-14.30
Data driven precision medicine - right treatment, right patient, right time
Dr. Anne-Marie Martin, Novartis Global Head of Precision Medicine
14.30-14.50
Boosting the Growth of Competitive Smart Health ecosystems
Dr. Minna Hendolin, Senior Director, Health and Wellbeing, Ecosystems, Business Finland
14.50-15.20
Break

Economy of wellbeing - how can we benefit from data?


15.20-15.40
How to solve economic challenges in countries with ageing population with Smart Health?
Mr. Pekka Ala-Pietilä, Sitra’s International Advisory panel
15.40-16.40
How can we benefit from Data
Session moderated by Dr. Sampo Sammalisto, Business Finland
Genome data for better future healthcare
Professor Markus Perola, Research Professor, National Institute for Health and Welfare (THL)
Health economics of prevention and treatment of type 2 diabetes
Professor Janne Martikainen, University of Eastern Finland, School of Pharmacy
Data-driven decision support for health
Dr. Jaakko Lähteenmäki, Principal Scientist, VTT Technical Research Centre of Finland
Transforming data to knowledge for better healthcare
Dr. Arho Virkki, Head of Auria Clinical Informatics at Turku University Hospital, Adjunct Professor of Medical Mathematics at University of Turku
16.40 – 17.00
Closing
Antti Viitanen, Novartis, Minna Hendolin, Business Finland, Janne Martikainen, University of Eastern Finland, Riitta Mustonen, University of Turku, Jaana Sinipuro, Sitra
17.00 – 18.30
Cocktails

Contact information

Public Affairs Kirsi Heikola, Novartis Finland, +358 40 7290801, kirsi.heikola@novartis.com

Communication Manager Sanna Melin, Novartis Finland, +358 40 1836321, sanna.melin@novartis.com

Speakers

Arho Virkki

Dr. Arho VirkkiInfo

Hartwig Huland

Hartwig Huland Info

Knut_Mager

Knut Mager Info

Leena Sarvaranta

Leena Sarvaranta Info

Silja Lindqvist

Silja Lindqvist Info

Lisa Witte-Stremmel

Lisa Witte-Stremmel Info

Johanna Seppänen

Johanna Seppänen Info

Minna Hendolin

Minna Hendolin Info

Mika Scheinin

Mika Scheinin Info

Dr. Arho Virkki

Dr. Arho Virkki is Head of Clinical Informatics at Auria Clinical Informatics, and an Adjunct Professor at Department of Mathematics and Statistics at the University of Turku.

His research interests include machine learning, data mining and mathematical modeling for decision support. At Auria, his key goals include providing researchers and specialists with high-quality patient data in pseudonymized or anonymized format to facilitate the development of data-informed approaches to precision medicine and safe, cost-effective treatment strategies.

Professor Dr. Hartwig Huland

Professor Dr. Hartwig Huland is the senior physician at the Prostate Centre at the Hamburg Eppendorf University Clinic. He founded this specialist clinic together with Professor Dr. Markus Graefen in 2005.

Professor Huland is a guest speaker in the 2019 edition of Harvard Business School's Intensive Course on Value Based Healthcare course.

Mr. Knut Mager

Head Global Data Privacy, Novartis
Knut Mager is Novartis’ Head Global Data Privacy and a member of the Advisory Board of the Future of Privacy Forum (FPF) and the Centre for Information Policy Leadership Advisory Council (CIPL). From April 2016 to June 2019, Knut chaired the Data Protection working group of European Federation of Pharmaceutical Industries and Associations (EFPIA).

Knut joined Novartis in 2003 as General Counsel, Head of Legal of the Sandoz Division. Since 2007, he held various leadership positions with Novartis Group Legal, inter alia Head of Commercial Legal and Head Country Legal Organizations.

Knut started his career in 1990 at Schering AG (now Bayer) in Berlin, Germany, where he held various positions including Head of Patents and Head Corporate Strategy. He is a German attorney-at-law (Rechtsanwalt) and INSEAD certified international director (IDP-C).

Leena Sarvaranta

Head of EU Affairs, VTT Technical Research Centre of Finland
Dr. Leena Sarvaranta is Head of EU Affairs at VTT since 2007. VTT is a fully state-owned, non-profit research organization with a specific public service mandate from the Finnish Ministry of Economic Affairs and Employment. VTT engages in active cooperation between various stakeholders.

Leena’s work is future-oriented and guided by strategic alignment of VTT actions for achieving sustainability and competitiveness at a national as well as the EU level through collaboration in research and innovation activities. Today, VTT is among the most active European research organizations participating in the EU research programmes. VTT is an active member of EARTO, European Association of Research and Technology Organisations, and takes part in constructive dialogue with European institutions, examining issues in a broad innovation policy context across traditional sectoral and administrative boundaries.

In 2014-2018, Leena served in the Strategic Research Council within the Academy of Finland, a funding mechanism for long-term research to support decision-making across society. As a member of the Government Foresight Group in 2016-2019, she took part in coordination of national foresight efforts. She also works in a coordination group for Smart Specialisation Strategy of Helsinki-Uusimaa Region.

Leena has contributed to various EU-level initiatives, more recently the Strategic Forum for Important Projects of Common European Interest (2018-2019). Her earlier activities include High Level Groups on Key Enabling Technologies (2010-2011, 2013-2015) as well as assessments of Contractual PPPs in FP7 and H2020.

Silja Lindqvist

Born with rare skin disease, ichtyosis, Silja Lindqvist met the first other person with a similar skin disease at the age of 18. She has been a voluntary worker for raising the awareness of rare diseases and ichtyosis as part of the Finnish Ichtyosis association actions. Silja is a founding member of the European Ichtyosis Network (ENI) and Board member in Allergy, Skin and Asthma Federation of Finland. She has a professional background as a programme manager related to digital services and data.

Lisa Witte-Stremmel

Since April 2019 Policy Advisor, Unit 511 “New technologies and data use”, Federal Ministry of Health

2017-2019 Policy Advisor, Unit 521 “Strategic issues relating to the national eHealth infrastructure agency (gematik), the eHealth infrastructure and eHealth”, Federal Ministry of Health

2014-2017 Policy Advisor for a member of the Deutsche Bundestag

2005-2011 M.A. Art History, History and Literature (Münster, Florence, Würzburg)

Johanna Seppänen

PhD in Biometrics, Director of Social and Health Data Permit Authority Findata

Johanna Seppänen works as director of the newly founded Finnish Social and Health Data Permit Authority Findata with the aim to institute the new authority and its functions.

She has previous positions as Head of Statistics at Statistics Finland Research Services, Head of Statistics and Health Economics at FIOH, Researcher at The Finnish Institute for Health and Welfare, The Social Insurance Institution of Finland Kela Research department and the Finnish Cancer Registry, and as Biostatistician in the pharmaceutical industry. Seppänen has also worked as a Lecturer at the University of Jyväskylä.

Johanna Seppänen is a strong professional with a PhD focused in Biometrics from the University of Helsinki, Faculty of Medicine. She is an experienced leader with track record of leading and developing public sector research infrastructures. Seppänen is skilled in register-based research, statistical methods and biostatistics, data management and lecturing. Her expertise also includes leadership, data protection and research ethical issues.

Johanna Seppänen has 15 peer reviewed articles in international journals and 11 other publications. She is a member of National Committee on Medical Research Ethics.

Dr. Minna Hendolin

Senior Director, Health and Wellbeing Ecosystems
Business Finland Oy

https://fi.linkedin.com/in/minna-hendolin-3382068
Twitter: @HendolinMinna

Minna Hendolin has been part of the health sector research, innovation and business ecosystem in multiple roles during the last 25 years. Starting from the academic research, continuing to commercialization of own research findings all the way up to the listed multinational biopharmaceutical company and global innovation policy. She has several years of experience in management and leadership both in SMEs and large corporations as well as in public organization. Since 2010, Dr. Hendolin has been working as a health and life science executive for government funding and innovation organizations, first at Tekes and later at Business Finland. At her current position as a Senior Director, she is leading the Health and Wellbeing thematic area at Business Finland covering innovation and export programs, international collaboration, funding and national strategic initiatives and policies. Dr. Hendolin belongs to the World Economic Forum Expert Group and is a member and speaker in Horasis Global Leaders Summit. Ms. Hendolin holds a doctoral degree in biochemistry and molecular biology.

Business Finland is the Finnish innovation funding, trade, investment, and travel promotion organization, headquartered in Helsinki. Business Finland is fully owned by the Finnish Government employing some 600 experts in 40 offices globally and in 20 regional offices around Finland. Business Finland is part of the Team Finland network. www.businessfinland.com 

Mika Scheinin

Mika Scheinin is Professor emeritus at the University of Turku, where he served as Professor of Clinical Pharmacology in 1995-2004 and as Professor of Pharmacology in 2004-2017. His main scientific interests include receptors and neurotransmitters in the central nervous system and the use of biomarkers as surrogate endpoints in early-phase clinical trials. He was the chairman of the Ethics Committee of the Hospital District of Southwest Finland from 1997 until 2018. Currently, Professor Scheinin is active in several early-phase clinical trials on pharmaceuticals as the Chief Scientific Officer of CRST Ltd., a contract research organization based in Turku, Finland.

×